Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics, Inc. (ZVSA) generates a steady flow of news related to its progress as a clinical-stage specialty biopharmaceutical company focused on renal and inflammatory diseases. Company press releases and SEC filings highlight developments around its two proprietary platforms: Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for chronic inflammatory and cardiometabolic conditions.
News coverage for ZyVersa frequently centers on clinical and preclinical milestones. For VAR 200, investors can follow announcements about the initiation and conduct of a phase 2a proof-of-concept trial in patients with diabetic kidney disease, plans for subsequent studies in focal segmental glomerulosclerosis and Alport syndrome, and use of VAR 200 under FDA-authorized Emergency Compassionate Use in a patient with ApoCII amyloidosis. Releases also discuss preclinical data showing reduced renal lipid accumulation, protection against renal injury and fibrosis, and improvement in proteinuria in multiple kidney disease models.
For IC 100, ZyVersa issues news highlighting preclinical data in cardiometabolic and neurological models, including effects on insulin resistance, vascular inflammation, and cardiac function, as well as plans for IND-enabling studies in a diet-induced obesity model and a future phase 1 trial in overweight subjects at risk for cardiometabolic conditions. The company also reports on scientific publications and review articles that, in its view, support the rationale for targeting inflammasomes and renal lipotoxicity.
Another recurring theme in ZyVersa’s news is corporate and capital markets activity. Releases describe equity purchase agreements, warrant inducement transactions, and financing arrangements intended to fund ongoing research and development, along with updates on its trading status following the delisting of its common stock from Nasdaq and quotation on the OTCQB Venture Market under the symbol ZVSA.
By monitoring this news page, readers can track ZyVersa’s reported clinical progress, preclinical findings, financing events, and regulatory and listing updates, all drawn from the company’s own press releases and related disclosures.
ZyVersa Therapeutics announced that CEO Stephen C. Glover will present key updates on its drug candidates during a fireside chat at the 35th Annual Roth Conference on March 14, 2023. The discussion will focus on the Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, which targets various inflammatory diseases. The event will take place at The Ritz Carlton, Laguna Niguel, California.
ZyVersa, listed on Nasdaq as ZVSA, specializes in developing innovative therapies for conditions with significant unmet medical needs.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) recently highlighted research published in Translational Research, revealing that traumatic brain injury (TBI) enhances inflammasome activation in Alzheimer's disease (AD), worsening cognitive outcomes. It notes that individuals with a history of moderate TBI are 2.3 times more likely to develop AD, according to CDC data. The study asserts that IC 100, an inflammasome ASC inhibitor, significantly reduces this inflammatory response in AD models post-TBI. ZyVersa aims to leverage this data to advance its therapeutic approach targeting inflammasome-related neurological disorders.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced on January 27, 2023, the grant of an inducement equity award to its new Chief Medical Officer, Dr. Pablo Guzman. The grant includes a nonqualified stock option for 100,000 shares at an exercise price of $2.11 per share, the closing price on January 25, 2023. This award, approved by the Board’s Compensation Committee, vests in three equal installments over three years, contingent on Dr. Guzman's continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with notable projects including VAR 200 and IC 100.
ZyVersa Therapeutics (Nasdaq: ZVSA), a clinical stage biopharmaceutical company, will present at the BIO CEO & Investor Conference on February 6, 2023, at 2:45 PM EST in New York City. CEO Stephen C. Glover will discuss the development of two key clinical assets: VAR 200, aimed at renal diseases, and IC 100, targeting damaging inflammation. VAR 200 is in Phase 2a for treating focal segmental glomerulosclerosis and other kidney diseases, while IC 100 addresses inflammation in various diseases. This presentation highlights ZyVersa's strategy, achievements, and upcoming milestones, potentially impacting investor confidence.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced a live webcast presentation by CEO Stephen C. Glover, scheduled for January 18, 2023, at 2:00 PM ET. The presentation will cover the company's advancements in its clinical programs for VAR 200, targeting renal diseases, and the potential of its inflammasome ASC inhibitor, IC 100.
The webcast will be available on ZyVersa's website, with a replay accessible for 90 days post-event. ZyVersa is focused on developing first-in-class therapies for patients with high unmet medical needs.
ZyVersa Therapeutics announced the appointment of three independent board members, expanding its board to seven. The new members include Gregory G. Freitag, J.D., CPA; Katrin Rupalla, PhD; and James Sapirstein. This strategic move aims to enhance the company’s leadership as it develops its lead drug candidates, VAR 200 for renal disease and IC 100 for inflammatory diseases. The board members bring extensive experience in the biopharmaceutical sector, with a strong focus on advancing clinical-stage products addressing significant unmet medical needs.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced the addition of Drs. Daniel C. Cattran and Fernando C. Fervenza to its Renal Scientific Advisory Board. Both are distinguished nephrologists expected to enhance the development of VAR 200, a phase 2a-ready cholesterol efflux mediator targeting renal lipid accumulation and kidney disease progression. VAR 200 aims to treat focal segmental glomerulosclerosis (FSGS) and other glomerular diseases. The company emphasizes the significance of their expertise in advancing clinical programs.